<DOC>
	<DOCNO>NCT00003231</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug surgery may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy docetaxel cisplatin follow surgery treating patient stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Surgery Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy toxic effect docetaxel plus cisplatin patient stage IIIA non-small cell lung cancer . II . Assess clinical pathological response rate therapy patient population . III . Compare benefit surgery term overall survival respond nonresponding patient . OUTLINE : Patients receive infusion docetaxel 1 hour day 1 , follow infusion cisplatin 1 hour day 1-2 . Treatment repeat three 21 day course . Patients undergo tumor resection mediastinal lymph node dissection . Patients receive postoperative radiotherapy within 4 week resection tumor reach resection margin and/or first mediastinal lymph node level involve . Patients follow death . PROJECTED ACCRUAL : Approximately 5-40 patient accrue within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIIA nonsmall cell lung cancer ( NSCLC ) ( include squamous , adenocarcinoma , large cell , poorly differentiate NSCLC ) Nodal metastases T13 N2 M0 No distant metastasis PATIENT CHARACTERISTICS : Age : 18 75 Performance Status : WHO 02 Life Expectancy : Not specify Hematopoietic : Leucocytes great 4,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin within normal limit AST ALT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal : Creatinine clearance great 60 mL/min No hypercalcemia Cardiovascular : No unstable cardiac disease No congestive heart failure No angina pectoris No significant arrhythmias No prior history myocardial infarction within 3 month Pulmonary : Lung function test force expiratory volume great 1.2 L/sec Neurologic : No dementia No peripheral neuropathy great grade 1 No psychosis No seizure disorder Other : No prior concurrent malignancy , except : Nonmelanoma skin cancer Carcinoma situ cervix No active uncontrolled infection serious medical condition No diabetes mellitus treat insulin No gastric ulcer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior corticosteroid endocrine therapy No concurrent treatment prednisone ( except prophylaxis , treatment acute hypersensitivity , chronic treatment initiate great 6 month prior study entry ) Radiotherapy : No prior radiotherapy Surgery : No prior surgery malignancy Other : No concurrent treatment experimental drug No involvement clinical trial within 30 day study No prior treatment cytostatic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>